These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 22615459)

  • 1. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
    Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ig gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjögren's syndrome patients.
    Hamza N; Hershberg U; Kallenberg CG; Vissink A; Spijkervet FK; Bootsma H; Kroese FG; Bos NA
    J Immunol; 2015 Jan; 194(2):514-21. PubMed ID: 25488989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minor salivary gland immunohistology in the diagnosis of primary Sjögren's syndrome.
    Salomonsson S; Rozell BL; Heimburger M; Wahren-Herlenius M
    J Oral Pathol Med; 2009 Mar; 38(3):282-8. PubMed ID: 18793250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
    Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
    Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients.
    Visser A; Doorenspleet ME; de Vries N; Spijkervet FKL; Vissink A; Bende RJ; Bootsma H; Kroese FGM; Bos NA
    Front Immunol; 2018; 9():491. PubMed ID: 29662487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
    Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
    Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
    Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
    Abdulahad WH; Kroese FG; Vissink A; Bootsma H
    J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FcRL4
    Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
    J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of CD4+ CD25+ regulatory T cells in peripheral blood and salivary gland of patients with primary Sjögren's syndrome].
    Li XM; Li XP; Qian L; Wang GS; Zhang H; Zhei ZM; Li Q; Chen K; Wang XQ; Wang YP
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1034-6. PubMed ID: 17672966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A
    Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of parotid gland biopsy in early detection of lymphoma in primary Sjogren's syndrome].
    Vasil'iev VI; Logvinenko OA; Probatova NA; Kokosadze NV; Gorodetskiĭ VR; Kovrigina AM; Kondrat'eva TT; Mitrikov BV; Gaĭduk IV; Safonova TN; Simonova MV; Radenska-Lopovok SG; Varlamova EIu
    Ter Arkh; 2009; 81(6):20-7. PubMed ID: 19663187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome.
    Gellrich S; Rutz S; Borkowski A; Golembowski S; Gromnica-Ihle E; Sterry W; Jahn S
    Arthritis Rheum; 1999 Feb; 42(2):240-7. PubMed ID: 10025917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
    Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
    Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab in primary Sjögren's syndrome: a ten-year journey.
    Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
    Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
    J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 antibody in primary Sjögren's syndrome management.
    Chen S; Liu Y; Shi G
    Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.